Small molecule · Inhibitor of cardiac myosin (MYH7) · developed by Cytokinetics
Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity. It reduces the force generated by myosin at the cardiac sarcomere, thereby reducing cardiac contractility and left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 16, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07600177 | Phase 4 | Hypertrophic Cardiomyopathy (HCM) | Recruiting | CYTK |
| NCT05767346 | Phase 3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | CYTK |
| NCT05186818 | Phase 3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Completed | CYTK |
| NCT04848506 | Phase 2/3 | Symptomatic Hypertrophic Cardiomyopathy (HCM) | Enrolling by invitation | CYTK |
| NCT04219826 | Phase 2 | Hypertrophic Cardiomyopathy (HCM) | Completed | CYTK |
| NCT04783766 | Phase 1 | Obstructive Hypertrophic Cardiomyopathy | Completed | CYTK |
| NCT03767855 | Phase 1 | Symptomatic Obstructive Hypertrophic Cardiomyopathy | Completed | CYTK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Symptomatic Hypertrophic Cardiomyopathy (HCM)Healthy Adult SubjectsHealthy SubjectsHypertrophic Cardiomyopathy (HCM)Obstructive Hypertrophic CardiomyopathyObstructive Hypertrophic Cardiomyopathy (oHCM)Symptomatic Obstructive Hypertrophic Cardiomyopathy
Updated Oct 3, 2026. Something wrong or missing? Report it on the CYTK page.
See CYTK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CYTK catalysts and pipeline →